BHP Attracts AI-Focused Investors as Copper Demand Surges 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 30, 2018 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended March 31, 2018 after the market closes on Tuesday, May 8th, 2018. AGTC management will host a conference call beginning at 4:30 pm Eastern Time that day to review results and provide a corporate update.
To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The passcode is 13678555. A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRS and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
AGTC IR/PR CONTACTS:
David Carey (IR) or Tom Vickery (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (646) 871-8482
[email protected] or [email protected]
CORPORATE CONTACTS:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
[email protected]
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected]
